Biblioteca
Alertas Bibliográficas
DIABETES
Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings.
Shaw JL, Bannuru RR, Beach L et al.
Diabetes Care. 2024.
https://doi.org/10.2337/dci24-0073
De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial (TRANSITION‐T2D).
Rodriguez P, Breslaw N, Xiao H et al.
Diabetes Obes Metab. 2024.
https://doi.org/10.1111/dom.16057
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke F, Horn P, Wai-Sun Wong V et al.
J Hepatol. 2024 Sep;81(3):492-542.
https://doi.org/10.1016/j.jhep.2024.04.031
High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring.
Tienstra M, de Boer JW, van Doesum JA et al.
Endocr Pract. 2024.
https://doi.org/10.1016/j.eprac.2024.09.013
Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis.
Lewis SJ, Williams CL, Mortimer GL et al.
Diabet Med. 2024.
https://doi.org/doi:10.1111/dme.15394
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ.
Diabetes Care. 2024 Jun 6:dci240003.
doi:10.2337/dci24-0003
ENDOCRINOLOGÍA
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, et al.
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21.
https://doi.org/10.1530/EJE-22-0689
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Margaret C S Boguszewski, Cesar L Boguszewski , et al.
Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52.
https://doi.org/10.1530/EJE-21-1186
Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop
John P Bilezikian 1, Aliya A Khan, et al.
J Bone Miner Res. 2022 Nov;37(11):2293-2314.
https://doi.org/10.1002/jbmr.4677
Genetics of Cushing’s disease: from the lab to clinical practice
Marily Theodoropoulou , Martin Reincke
Pituitary. 2022 Oct;25(5):689-692.
https://doi.org/10.1007/s11102-022-01253-9
Tumor-induced Osteomalacia: A Comprehensive Review
Salvatore Minisola , Seiji Fukumoto, et al.
Endocr Rev. 2023 Mar 4;44(2):323-353.
https://doi.org/10.1210/endrev/bnac026
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies
Antonio Marcondes Lerario, Dipika R Mohan, Gary D Hammer, et al.
Endocr Rev. 2022 Nov 25;43(6):1051-1073.
https://doi.org/10.1210/endrev/bnac012
PEDIATRÍA
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al.
N Engl J Med. 2019 Aug 15;381(7):637-646.
http://doi.org/10.1056/NEJMoa1903822
Could AGE/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity?
Corica D, Aversa T, Ruggeri RM, Cristani M, Alibrandi A, et al.
Front Endocrinol (Lausanne). 2019 Jun 28;10:426.
http://doi.org/10.3389/fendo.2019.00426
Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Goedegebuure WJ, Hokken-Koelega ACS.
Horm Res Paediatr. 2019 Aug 7:1-5.
http://doi.org/10.1159/000501746
Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome.
Singh P, Mahmoud R, Gold JA, Miller JL, Roof E, Tamura R, et al.
J Med Genet. 2018 May 18. pii: jmedgenet-2017-105118.
http://doi.org/10.1136/jmedgenet-2017-105118
Neonatal Features of the Prader-Willi Syndrome; The Case for Making the Diagnosis During the First Week of Life.
Çizmecioğlu FM, Jones JH, Paterson WF, Kherra S, Kourime M, McGowan R, et al.
J Clin Res Pediatr Endocrinol. 2018 Jul 31;10(3):264-273.
http://doi.org/10.4274/jcrpe.0029
Growth hormone – past, present and future.
Ranke MB, Wit JM.
Nat Rev Endocrinol. 2018 May;14(5):285-300
http://doi.org/10.1038/nrendo.2018.22
CIENCIAS BÁSICAS
Mechanisms of Insulin Action and Insulin Resistance.
Petersen MC, Shulman GI.
Physiol Rev. 2018 Oct 1;98(4):2133-2223.
http://doi.org/10.1152/physrev.00063.2017
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Buzzetti E, Pinzani M, Tsochatzis EA.
Metabolism. 2016 Aug;65(8):1038-48.
http://doi.org/10.1016/j.metabol.2015.12.012
DNA methylation in the pathogenesis of type 2 diabetes in humans.
Davegårdh C, García-Calzón S, Bacos K, Ling C.
Mol Metab. 2018 Feb 7. pii: S2212-8778(17)31102-X.
https://doi.org/10.1016/j.molmet.2018.01.022
Effect of Iodothyronines on Thermogenesis: Focus on Brown Adipose Tissue.
Cioffi F, Gentile A, Silvestri E, Goglia F, Lombardi A.
Front Endocrinol (Lausanne). 2018 May 23;9:254.
http://doi.org/10.3389/fendo.2018.00254
eCollection 2018. Review. PubMed PMID: 29875734; PubMed Central PMCID: PMC5974034.
MicroRNA-204-5p regulates 3T3-L1 preadipocyte proliferation, apoptosis and differentiation.
Du J, Zhang P, Gan M, Zhao X, Xu Y, Li Q et al.
Gene. 2018 Aug 20;668:1-7.
http://doi.org/10.1016/j.gene.2018.05.036
Epub 2018 May 18. PubMed PMID: 29775748.
The Circadian Clock in White and Brown Adipose Tissue: Mechanistic, Endocrine, and Clinical Aspects.
Froy O, Garaulet M.
Endocr Rev. 2018 Jun1;39(3):261-273.
http://doi.org/10.1210/er.2017-00193
PubMed PMID: 29490014